Quizartinib Bests Chemo for FLT3-Mutant AML.
The FLT3 inhibitor quizartinib provided a survival benefit over chemotherapy in a phase III trial of patients with relapsed or refractory FLT3-mutant acute myeloid leukemia. The drug, along with other FLT3 inhibitors, could become a first-line treatment based on results from ongoing studies.